DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



A Study of Efficacy of Treatment With Bortezomib (in Combination With Doxorubicin and Dexamethasone) in Previously Untreated Patients With Multiple Myeloma

Information source: Janssen-Cilag Pty Ltd
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Multiple Myeloma

Intervention: PAD induction (Drug)

Phase: Phase 2

Status: Completed

Sponsored by: Janssen-Cilag Pty Ltd

Official(s) and/or principal investigator(s):
Janssen-Cilag Pty Ltd Clinical Trial, Study Director, Affiliation: Janssen-Cilag Pty Ltd

Summary

The purpose of this study is to determine efficacy of treatment with bortezomib (in combination with doxorubicin and dexamethasone) in previously untreated patients with Multiple Myeloma.

Clinical Details

Official title: A Phase II Trial of Bortezomib, Doxorubicin and Dexamethasone (PAD) Induction Therapy in Patients With Untreated Multiple Myeloma (MM), Stratified for Markers of Bortezomib Resistance

Study design: Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Overall Response Rate (ORR): Number of Participants Who Are Responders (Had Stringent Complete Response [sCR], CR, Very Good Partial Response [VGPR] or Partial Response [PR]) After 4 Cycles of Bortezomib, Doxorubicin and Dexamethasone (PAD) Induction

Secondary outcome:

Disease Response After 4 Cycles of Bortezomib, Doxorubicin and Dexamethasone (PAD) Induction

Overall Response Rate (ORR) to Bortezomib, Doxorubicin and Dexamethasone (PAD) Induction 3-months Following Autologous Stem Cell Transplant (ASCT).

Disease Response 3-months After Autologous Stem Cell Transplant (ASCT)

Event Free Survival (EFS)

Overall Survival

Assessment of Quality of Life (AQoL) Scores

Overall Response Rate (ORR) Stratified by Protein Expression (p53)

Overall Response Rate (ORR) Stratified by Protein Expression (Cyclin D1).

Overall Response Rate (ORR) Stratified by Protein Expression (Bcl-2)

Overall Response Rate (ORR) Stratified by Protein Expression (FGFR3)

Overall Survival (OS) Stratified by Protein Expression (p53).

Overall Survival (OS) Stratified by Protein Expression (Cyclin D1)

Overall Survival (OS) Stratified by Protein Expression (Bcl-2)

Overall Survival (OS) Stratified by Protein Expression (FGFR3)

Detailed description: This is an open-label, single-arm, multicentre study which will enroll approximately 105 patients. Open-label means all people involved in the study know the identity of the intervention. Single-arm means there is one group of patients, all receiving the same treatment. Four 21-day cycles of a combination of bortezomib i. v. (intravenous) 1. 3 mg/m2 (Days 1, 4, 8 and 11), doxorubicin i. v. 20 mg/m2 (days 1 and 4) and dexamethasone p. o. (by mouth) (days 1, 2, 4, 5, 8, 9, 11 and 12) (PAD) will be given. Patients will be discontinued if disease progresses, or unacceptable treatment-related toxicity occurs. Following PAD treatment, patients will have peripheral blood stem cells (PBSC) collected, and an autologous stem cell transplant (ASCT) will be performed. Patients will then make monthly visits to the Study Doctor until 1 year after start of treatment, and attend a final follow-up visit at 2 years. Efficacy assessment of response to PAD will be made using the International Myeloma Working Group (IMWG) criteria. The primary outcome is to compare the overall response rate following 4 cycles of PAD induction therapy between patients with and without extra copies of the long arm of the first chromosome (1q21) measured by fluorescent in situ hybridisation (FISH) in their marrow at baseline. Patient reported outcomes will be assessed using the AQoL (Assessment of Quality of Life). Safety will be evaluated throughout the study by assessment of adverse events including changes in physical examination, concomitant medication, ECOG (Eastern Cooperative Oncology Group) scores, vital signs and clinical laboratory findings. A sample size of 105 provides 80% power (a=0. 05) to detect a difference in overall response rate of 28% at the end of 4 cycles of PAD. This is based on the assumptions that 44% of patients have amplification of 1q21 1, 2, the overall response rate with PAD combination therapy is 80%; the overall response rate with PAD if PAD therapy does not overcome 1q21 amplification is assumed to be 64%, while without 1q21 amplification it is assumed to be 92%. That is: Overall Response Rate (ORR) = P1q21 amplified x ORRamplified + P1q21 not amplified x ORRnot amplified i. e. 80% = 44% x 64% + 56% x 92%. The sample size of 105 allows for a 20% drop-out rate. Four 21-day cycles of PAD: a combination of bortezomib i. v. (intravenous) 1. 3 mg/m2 (Days 1, 4, 8 and 11), doxorubicin i. v. 20 mg/m2 (days 1 and 4) and dexamethasone p. o. (by mouth) (days 1, 2, 4, 5, 8, 9, 11 and 12).

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Previously diagnosed with multiple myeloma

- eligible for autologous stem cell transplantation

- meets pre-treatment lab criteria (as defined within protocol).

Exclusion Criteria:

- Previously received treatment for multiple myeloma (including prior therapy with

radiation or pulsed dexamethasone), except localised radiation to a solitary lesion or plasmacytomas or 4 days of corticosteroid therapy

- have a current diagnosis of smoldering multiple myeloma, monoclonal gammopathy of

undetermined significance (MGUS), or Waldenström Macroglobulinemia

- have a history of any other malignancy within 5 years before enrolment

- have other significant comorbidities.

Locations and Contacts

Adelaide, Australia

Box Hill, Australia

Brisbane, Australia

Camperdown, Australia

Geelong, Australia

Gosford, Australia

Greenslopes, Australia

Malvern, Australia

Melbourne, Australia

Parkville, Australia

Perth, Australia

Sydney, Australia

Westmead, Australia

Woden, Australia

Wollongong, Australia

Woolloongabba N/A, Australia

Additional Information

Starting date: January 2009
Last updated: May 7, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017